ANDA 204772, held by Alvogen. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 204772 (Methylphenidate Hydrochloride), held by Alvogen, was first approved by FDA on Feb 29, 2016, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 29, 2016 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride10MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride20MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Sep 23, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 28, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 21, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 27, 2019 | Supplement 7Manufacturing | Approved | None posted |
| Feb 29, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters